Table 2.
| Baseline | Posttreatment | p value | |
|---|---|---|---|
| Neuropathy symptom score (NSS) | |||
| Placebo | 5.8 (0.7) | 5.0 (0.7) | NS |
| RBX-32 | 5.3 (0.7) | 4.2 (0.7) | NS |
| TPX | 5.6 (2.3) | 4.3 (0.65) | .007 |
| Sensory score (SS) | |||
| Placebo | 7.7 (1.5) | 5.9 (1.2) | NS |
| RBX-32 | 5.7 (0.8) | 4.0 (0.8) | NS |
| TPX | 15.5 (1.79) | 8.3 (1.19) | <.001 |
| Motor score (MS) | |||
| Placebo | 3.5 (0.4) | 2.4 (0.4) | .03 |
| RBX-32 | 1.7 (0.3) | 1.6 (0.3) | NS |
| TPX | 3.3 (0.8) | 3.8 (0.9) | NS |
| Neuropathy impairment score (SS + MS) | |||
| Placebo | 11.3 (1.7) | 8.3 (1.3) | NS |
| RBX-32 | 7.4 (1.0) | 5.6 (0.9) | NS |
| TPX | 18.8 (2.15) | 12.1 (1.71) | .003 |
| Total neuropathy score (NIS + NSS) | |||
| Placebo | 17.0 (2.1) | 13.3 (1.8) | NS |
| RBX-32 | 12.7 (1.5) | 9.8 (1.3) | NS |
| TPX | 24.35 (2.61) | 16.35 (2.02) | .001 |
| NTSS-6 | |||
| Placebo | 5.04 (1.12) | 4.38 (1.15) | NS |
| RBX-32 | 4.38 (0.75) | 1.49 (0.38) | <.001 |
| TPX | 7.57 (1.3) | 4.26 (0.95) | .036 |
NS, not significant.
a
Data are presented as mean (± SEM).
b
Within-group analysis was performed using Wilcoxon signed-rank test.